Examples of using Biodistribution in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Non-clinical biodistribution.
Biodistribution,(b) degradation,(c) side-effects.
Glycosylation of other proteins is known to affect their stability,activity, biodistribution, and half-life in blood.
Clinical biodistribution, elimination, and shedding.
A carrier may alter the temporal or spatial delivery,changing the biodistribution of the pharmacokinetics of the drug.
A 4-month biodistribution study was performed in mice.
Platform Z02 provides a multi-step approach for preclinical assessment of toxicity,bioavailability and biodistribution of peptides as well as novel transporter and labeling systems.
Biodistribution(within the body) and viral shedding excretion/secretion.
Immunosuppressant co-treatment did not influence the biodistribution pattern neither at low dose nor at high dose in mice.
Biodistribution The factors which affect the biodistribution of nanoparticles are as follows.
As yttrium-90 forms a stable complex with ibritumomab tiuxetan, the biodistribution of the radiolabel follows the biodistribution of the antibody.
The biodistribution and shedding of intralesionally administered talimogene laherparepvec are being investigated in a melanoma study.
Nanoparticles that are intrinsically fluorescent remain completely unaffected by interaction with biomoleculesin terms of the brightness of their fluorescence, though this is detrimental to biodistribution and retention time.
Pharmacokinetic, biodistribution and dosimetry data have been obtained from 3 phase I studies.
For radiopharmaceuticals, studies should be designed to assess: a the in vivo stability of the radionuclide complex;b the animal biodistribution of the radionuclide; c the potential chemical toxicity; d the radiation exposure of tissues resulting from administration of the rad iopharmaceutIcaI.
In two similar studies of biodistribution and a phase II clinical study, mean quantitative uptake values in PET images differed between pAD and HV subjects in most examined areas of the brain.
The small size of nanobodies allows them to diffuse through the body with a biodistribution that matches that of the small venom toxin, and after the nanobody captures the venom, the complex is still small enough to be rapidly eliminated by the kidneys.
Pharmacokinetic, biodistribution and dosimetry data were obtained in 6 patients at an activity of 110 kBq/kg given twice, 6 weeks apart, and in 10 patients at an activity of 55, 110 or 221 kBq/kg.
The dosimetry estimates are based on biodistribution data provided by ICRP-30, showing bone, liver and kidneys as the significant target organs for the biodistribution of lutetium.
The particles determine the biodistribution and the release of copper ions, whereas the toxicity is comparable to cupper ions or other soluble nanomaterials.
Therefore, its pharmacokinetics and biodistribution are driven by the site of intralesional injection, tumour-selective replication, and release from tumour tissue.
One of the critical factors for biodistribution is the size of the naonparticles, where smaller gold nanoparticles were present in larger numbers in tissues compared to larger particles.
The dosimetry estimates were based on clinical biodistribution studies using methods developed for radiation dose calculations by the Medical Internal Radiation Dose(MIRD) Committee of the Society of Nuclear Medicine.